Introductory Chapter: Molecular Diagnostics in the Era of Precision Medicine

2.1 Polymerase chain reaction and its diagnostic utility

Since its introduction by Kary Mullis in the 1980s [1], the polymerase chain reaction (PCR) has become one of the most widely used and influential techniques in molecular biology and clinical diagnostics. PCR enables the exponential amplification of specific DNA sequences, allowing for the detection of nucleic acids with high specificity and sensitivity. PCR is widely used for detecting genetic mutations, identifying pathogens, genotyping, and analyzing inherited disorders. In clinical settings, PCR facilitates early diagnosis of infectious diseases, prenatal genetic screening, and confirmation of somatic mutations in cancer [8]. The technique’s adaptability, speed, and relative cost-effectiveness have made it indispensable in both research and diagnostic settings. The technique’s versatility and simplicity have led to numerous variations, including reverse transcription PCR (RT-PCR) for RNA analysis and quantitative PCR (qPCR) for real-time quantification of nucleic acids, further expanding its diagnostic utility.

Despite the emergence of high-throughput technologies, PCR continues to be a first-line diagnostic tool. Its enduring relevance underscores its critical role in the era of precision medicine and molecularly guided clinical decision-making. However, conventional PCR is primarily a qualitative method, providing presence-or-absence information without offering precise quantification. It also requires post-amplification steps such as gel electrophoresis, which increase contamination risk and processing time. These limitations have driven the development of more advanced amplification technologies, such as quantitative real-time PCR (qPCR) and digital PCR (dPCR), which allow for more accurate, real-time quantification of nucleic acids.

2.2 Real-time PCR and quantitative PCR (qPCR)

Real-time PCR, and quantitative PCR (qPCR) variant, is a molecular technique that enables the detection and quantification of nucleic acids during the exponential phase of amplification. In contrast to conventional endpoint PCR, which detects amplicons only after the completion of all cycles, real-time PCR monitors the accumulation of target DNA in real time by measuring fluorescence emitted by intercalating dyes (e.g., SYBR Green) or sequence-specific probes (e.g., TaqMan). The intensity of the fluorescence signal directly correlates with the amount of nucleic acid present, allowing for either relative or absolute quantification, depending on assay design.

qPCR has become a cornerstone of molecular diagnostics, valued for its high sensitivity, specificity, and rapid turnaround time. Its ability to perform amplification and quantification in a closed-tube system minimizes contamination risk and makes it compatible with high-throughput diagnostic workflows. Clinically, qPCR is routinely employed in various disease testing such as HIV [9], SARS-CoV-2 [10], detection of somatic mutations e.g., BCR-AB gene expression profiling [11], and quantification of circulating microRNAs [12] or cell-free nucleic acids, [13].

Despite its versatility and broad adoption, qPCR presents several limitations. These include reduced accuracy at very low target concentrations, difficulties in detecting small fold-changes, and susceptibility to PCR inhibitors or sample variability. Additionally, the need for normalization against reference genes and the use of standard curves introduces variability in quantification. To overcome these challenges, digital PCR (dPCR) has emerged as a next-generation method offering absolute quantification without the need for reference standards or calibration curves. The following section will explore the principles and clinical relevance of this emerging technology.

2.3 Digital PCR (dPCR) and its droplet-based variant

Digital PCR (dPCR) represents a significant advancement in nucleic acid quantification, enabling absolute measurement of DNA or RNA molecules without the need for standard curves [14]. Unlike traditional qPCR, which provides relative quantification based on amplification kinetics, dPCR works by partitioning the sample into thousands or even millions of individual reactions, such that each partition contains either zero or one (or a few) target molecules. Following PCR amplification, partitions are scored as positive or negative, and the number of target molecules is calculated using Poisson statistics. Among the various dPCR platforms, droplet digital PCR (ddPCR) is the most widely adopted. In ddPCR, the sample is emulsified into nanoliter-sized droplets, each serving as an independent microreactor [15]. This technique provides high sensitivity, precision, and tolerance to PCR inhibitors, making it particularly valuable for applications such as rare mutation detection, quantification of low-abundance transcripts, microRNA profiling, and monitoring of minimal residual disease.

Numerous studies have highlighted the advantages of droplet digital PCR (ddPCR) in clinical and research settings, particularly in applications where sensitivity and absolute quantification are critical [14]. For instance, ddPCR has been successfully used to quantify circulating tumor DNA (ctDNA) in oncology, allowing detection of rare mutations such as EGFR T790M in non-small cell lung cancer patients, even at allele frequencies below 0.1% [16]. In virology, ddPCR has demonstrated superior accuracy in monitoring viral load in HIV and SARS-CoV-2, especially when conventional qPCR methods yielded inconclusive results due to low copy numbers [17]. In neurodegenerative research, ddPCR has been employed to measure microRNA expression levels in cerebrospinal fluid and brain tissue, providing reproducible data despite the presence of inhibitors common in complex biological matrices [18]. These findings consistently support ddPCR as a highly sensitive and reproducible method, with a strong potential to complement or even replace traditional qPCR in specific diagnostic and monitoring applications.

Droplet digital PCR (ddPCR) has also emerged as a powerful tool for quantifying exon skipping efficiency in RNA-based therapeutic strategies, particularly in the context of neuromuscular disorders such as Duchenne muscular dystrophy (DMD). Exon skipping aims to restore the reading frame of defective mRNAs by using antisense oligonucleotides (AONs) to exclude specific exons during splicing. ddPCR allows for precise quantification of both skipped and non-skipped transcript isoforms, even when present at low levels [19], by using isoform-specific primer-probe sets. Compared to conventional RT-qPCR, ddPCR provides absolute counts of target molecules, increased reproducibility, and better sensitivity in detecting subtle changes in splicing patterns. Several studies have validated ddPCR as a reliable method for measuring exon skipping efficiency in preclinical and clinical settings, supporting its use in monitoring therapeutic response and optimizing dosing regimens for exon-skipping agents [20, 21].

While digital PCR has significantly advanced the precision of nucleic acid quantification, its utility remains limited to known sequences and predefined targets. To explore broader genetic landscapes, detect novel variants, or analyze complex transcriptomes, more comprehensive approaches are required [22]. To overcome these limitations and to enable the discovery of novel variants, structural rearrangements, and global expression changes, high-throughput sequencing technologies—such as next-generation sequencing (NGS)—have become essential tools in modern molecular diagnostics.

2.4 Sequencing

Sequencing is a fundamental technique in molecular biology that enables the determination of the precise order of nucleotides in DNA or RNA molecules [23]. Over time, sequencing technologies have evolved from first-generation methods such as Sanger sequencing to high-throughput approaches like next-generation sequencing (NGS) and, more recently, third-generation platforms, including nanopore and single-molecule real-time (SMRT) sequencing [24]. While Sanger sequencing remains valuable for small-scale, high-accuracy applications [25], NGS allows for parallel sequencing of millions of fragments, enabling genome-wide analyses. Third-generation sequencing adds the advantage of long-read capabilities, which is useful in structural variant detection and complex genome assembly [26]. Together, these technologies have revolutionized diagnostics, personalized medicine, and biomedical research by enabling comprehensive and detailed insights into genetic and epigenetic landscapes.

A landmark study published in Nature Communications [27] highlighted the clinical value of third-generation long-read sequencing (LRS) in genetic diagnostics. Researchers implemented an innovative analytical workflow that combined filters for single nucleotide variants (SNVs), structural variations, and genome-wide epigenetic patterns. In a positive control cohort (n = 76), the method successfully identified all known pathogenic variants, including SNVs, rearrangements, and methylation changes. Among 51 patients who had previously received no diagnosis through conventional short-read methods, LRS provided additional diagnostic insights in 10% of cases, notably uncovering epigenetic signatures relevant to spinal muscular atrophy. This study underscores the potential of LRS as a feasible “all-in-one” approach for clinical genetic diagnostics and rare disease variant discovery.

Despite their transformative capabilities, sequencing technologies face several challenges, including high costs, data interpretation complexity, storage burden, and the need for sophisticated bioinformatics pipelines. Additionally, incidental findings or variants of uncertain significance (VUS) raise ethical and clinical interpretation issues that require cautious management in diagnostic workflows [28].

2.5 Liquid biopsy/cell-free DNA (cfDNA) assay/ctDNA/diagnostic prenatal

Liquid biopsy is a minimally invasive diagnostic approach that enables the detection and analysis of molecular biomarkers—such as circulating tumor DNA (ctDNA), cell-free RNA, exosomes, and circulating tumor cells (CTCs)—from body fluids, most commonly blood [29]. Unlike traditional tissue biopsies, which require invasive sampling of solid tumors, liquid biopsies offer a real-time snapshot of systemic disease, allowing for longitudinal monitoring of tumor evolution, treatment response, and minimal residual disease [30]. This technique has proven especially valuable in oncology [31], where it supports early cancer detection, identification of actionable mutations, and detection of resistance mechanisms [31]. Beyond cancer, liquid biopsy is increasingly explored in areas such as prenatal diagnostics, organ transplantation, and neurodegenerative disease, highlighting its broad potential in personalized medicine and noninvasive disease management [32, 33].

Cell-free DNA (cfDNA) analysis has revolutionized non-invasive prenatal testing (NIPT) by enabling early detection of fetal genetic abnormalities from maternal blood samples [34]. Originating primarily from placental trophoblasts, fetal cfDNA represents a small fraction of the total circulating DNA in maternal plasma, typically as low as 5–15% in early pregnancy [35]. To accurately detect chromosomal aneuploidies such as trisomy 21, 18, and 13—or even single-gene disorders—analytical techniques must achieve exceptional sensitivity and specificity [36]. Droplet digital PCR (ddPCR) has proven particularly useful in this context due to its ability to perform absolute quantification of rare fetal alleles within a high maternal DNA background. Unlike conventional qPCR, ddPCR partitions the sample into thousands of nanoliter droplets, improving resolution and detection limits. Studies have shown that ddPCR-based assays can distinguish subtle allelic imbalances, detect paternal mutations inherited by the fetus, and even quantify fetal fraction, making it a valuable complement or alternative to next-generation sequencing in targeted prenatal applications [37].

As liquid biopsy technologies continue to evolve, their integration into routine clinical workflows offers the promise of earlier diagnosis [38], more precise risk stratification [39], and dynamic monitoring of disease. While challenges remain—such as standardization, cost-effectiveness, and data interpretation—ongoing advances in digital PCR, sequencing, and bioinformatics are rapidly addressing these barriers. The growing clinical utility of liquid biopsy underscores its central role in the future of noninvasive molecular diagnostics. Moreover, emerging multi-analyte approaches that combine cfDNA, cfRNA, and protein biomarkers from the same sample are paving the way for more comprehensive molecular profiling from a single liquid biopsy.